RSS-Feed abonnieren
DOI: 10.1055/s-0042-100825
Seltene Ursache einer transfusionspflichtigen gastrointestinalen Blutung
A rare cause of severe gastrointestinal bleedingPublikationsverlauf
Publikationsdatum:
16. März 2016 (online)
![](https://www.thieme-connect.de/media/dmw/201606/lookinside/thumbnails/0414_10-1055-s-0042-100825-1.jpg)
Zusammenfassung
Obere gastrointestinale Blutungen sind ein häufiges internistisches Krankheitsbild. Dieser Fallbericht beschreibt eine schwere transfusionspflichtige obere GI-Blutung aufgrund eines Angiosarkoms. Wie in diesem Fall geschildert, kann die tatsächliche Ursache der GI-Blutung zunächst unklar bleiben. Hier ist eine wiederholte Histologie-Gewinnung zwingend notwendig, um die Diagnose zu sichern und so eine adäquate Therapie zu ermöglichen. Beim primären gastrointestinalen Angiosarkom, einem extrem seltenen, hochaggressiven malignen Tumor mit multifokalem Wachstum und frühzeitiger Metastasierung, stellt die radikale OP die einzige kurative Behandlungsoption dar. Eine frühzeitige Diagnosestellung ist daher entscheidend. Palliative Therapieansätze bei metastasiertem Angiosarkom sind aktuell Inhalt klinischer Studien.
Abstract
Upper gastrointestinal hemorrhage represents a common symptom in the internal medical practice. This Case Report depicts a severe gastrointestinal bleeding from an angiosarcoma that required multiple blood transfusion. As shown in this case, the actual cause may initially remain unclear. Repeated tissue sampling is mandatory to confirm a diagnosis and provide adequate treatment. Primary gastrointestinal angiosarcomas are extremely rare and highly aggressive malignant tumors that tend to grow multifocally and metastasise early. The only curative treatment option is radical surgery, thus an early stage diagnosis is crucial. Palliative care for metastatic angiosarkoma is currently a topic for clinical studies.
-
Literatur
- 1 Silverstein FE, Gilbert DA, Tedesco FJ et al. The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc 1981; 27: 80-93
- 2 Ni Q, Shang D, Peng H et al. Primary angiosarcoma of the small intestine with metastasis to the liver: a case report and review of the literature. World J Surg Oncol 2013; 11: 242
- 3 Al Ali J, Ko HH, Owen D et al. Epithelioid angiosarcoma of the small bowel. Gastrointest Endosc 2006; 64: 1018-1021
- 4 Grewal JS, Daniel AR, Carson EJ et al. Rapidly progressive metastatic multicentric epithelioid angiosarcoma of the small bowel: a case report and a review of literature. Int J Colorectal Dis 2008; 23: 745-756
- 5 Liu DS, Smith H, Lee MM et al. Small intestinal angiosarcoma masquerading as an appendiceal abscess. Ann R Coll Surg Engl 2013; 95: e22-24
- 6 Vogt T, Brockmeyer N, Kutzner H et al. S1 Kurzleitlinie – Angiosarkom der Haut und Kaposi-Sarkom. J Dtsch Dermatol Ges 2013; 11: 2-10
- 7 Allison KH, Yoder BJ, Bronner MP et al. Angiosarcoma involving the gastrointestinal tract: a series of primary and metastatic cases. Am J Surg Pathol 2004; 28: 298-307
- 8 Khalil M.F. et al., Epithelioid angiosarcoma of the small intestine after occupational exposure to radiation and polyvinyl chloride: A case report and review of Literature. Sarcoma 2005; 9: 161-164
- 9 Saad A, Cappell MS, Amin M. Endoscopic findings with GI angiosarcoma correspond with the propensity of these vascular tumors to cause GI bleeding: two case reports and review of the literature. Dig Dis Sci 2013; 58: 1797-1801
- 10 Chen JL, Mok KT, Tseng HH et al. Duodenal angiosarcoma: an unusual cause of severe gastrointestinal bleeding. J Chin Med Assoc 2007; 70: 352-355
- 11 Maeyashiki C, Nagata N, Uemura N. Angiosarcoma involving solid organs and the gastrointestinal tract with life-threatening bleeding. Case Rep Gastroenterol 2012; 6: 772-777
- 12 Nagano T, Tai Y, Higashida Y et al. Docetaxel monotherapy for angiosarcoma in an elderly patient. Arch Dermatol 2007; 143: 1602-1603
- 13 Ionescu S, Barbu E, Ionescu C et al. Giant gastrointestinal stromal tumor of the stomach. Rom J Morphol Embryol 2015; 56: 239-245
- 14 Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104: 361-366
- 15 Vogt T, Hafner C, Bross K et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003; 98: 2251-2256
- 16 Fata F, O’Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-2037
- 17 Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275